KennethFrederickGrossmannMDPhD

Oncology • Princeton, NJ

Genitourinary Oncology, Melanoma

Instructor, Internal Medicine, University of Utah School of Medicine

Join to view full profile

Dr. Grossmann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Grossmann's full profile

Already have an account?

Office
Rahway -
Princeton, NJ 08540
Phone+1 801-865-2334
Is this information wrong?

Education & Training

University of Utah HealthFellowship, Hematology and Medical Oncology, 2007 - 2009
Oregon Health & Science UniversityFellowship, Hematology and Medical Oncology, 2006 - 2007
Oregon Health & Science UniversityResidency, Internal Medicine, 2004 - 2006
Oregon Health and Science University School of MedicineClass of 2004

Certifications & Licensure

OR State Medical License 2023 - 2025
UT State Medical License 2007 - 2024
FL State Medical License 2018 - 2020
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the Liver Start of enrollment: 2008 Jul 01
Completed
Phase 1
Radiation Use During Vemurafenib Treatment Start of enrollment: 2017 Jun 01
Withdrawn
Phase 1
Vemurafenib:Radiation Use During Vemurafenib Treatment Start of enrollment: 2014 Aug 01
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Start of enrollment: 2014 May 29
Completed
Phase 3
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma Start of enrollment: 2014 Jul 23
Completed
Phase 2
High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Start of enrollment: 2015 Nov 10
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.
Isabella C Glitza, Yongwoo David Seo, Christine N Spencer, Jennifer R Wortman, Elizabeth M Burton, Farah A Alayli, Christopher P Loo, Shikha Gautam, Ashish Damania, Ju...> ;Cancer Discovery. 2024 Apr 4
123 citations
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright Jr, Kathleen J Yost, John R Hyngstrom, Siwen Hu-Lieskovan, Christopher D Lao, Leslie A Fecher, Thach-Giao Truon...> ;The New England Journal of Medicine. 2023 Mar 2
19 citations
Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma.
Kenneth F. Grossmann, Megan Othus, Sapna Pradyuman Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp, Teresa M. Petrella, Thach-Giao Truong, Nikhil I. Khusha...> ;Cancer Discovery. 2021 Nov 11
11 citations
The dark side of immunotherapy.
Nwanneka Okwundu, Douglas Grossman, Siwen Hu-Lieskovan, Kenneth F. Grossmann, Umang Swami> ;Annals of Translational Medicine. 2021 Jun 1
38 citations
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.
Yousef Zakharia, Robert R. McWilliams, Olivier Rixe, Joseph J. Drabick, Montaser Shaheen, Kenneth F. Grossmann, Ravindra Kolhe, Rafal Pacholczyk, Ramses F. Sadek, Luci...> ;Journal for Immunotherapy of Cancer. 2021 Jun 11
136 citations
Melanoma: Cutaneous, Version 2.2021 Featured Updates to the NCCN Guidelines
Susan M. Swetter, John A. Thompson, Mark R. Albertini, Christopher A. Barker, Joel M. Baumgartner, Genevieve M. Boland, Bartosz Chmielowski, Dominick J. DiMaio, Alison...> ;Journal of the National Comprehensive Cancer Network. 2021 Apr 1
15 citations
Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma.
Rebecca Pokorny, Jordan P. McPherson, Benjamin Haaland, Kenneth F. Grossmann, Carolyn Luckett, Benjamin Newell Voorhies, Daniel S. Sageser, Jocelyn Wallentine, Zachary...> ;Journal for Immunotherapy of Cancer. 2021 Jan 1
65 citations
Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial
Alain Algazi, Megan Othus, Adil Daud, Roger S. Lo, Janice M. Mehnert, Thach Giao Truong, Robert M. Conry, Kari Kendra, Gary C. Doolittle, Joseph I. Clark, Michael J. M...> ;Nature Medicine. 2020 Oct 5
55 citations
Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit
Douglas Grossman, Nwanneka Okwundu, Edmund K. Bartlett, Michael A. Marchetti, Megan Othus, Daniel G. Coit, Rebecca I. Hartman, Sancy A. Leachman, Elizabeth G. Berry, L...> ;JAMA Dermatology. 2020 Sep 1
3 citations
Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 an...
Kelsey Baron, Justin C. Moser, Shiven B. Patel, Kenneth F. Grossmann, Sarah Colonna, John R. Hyngstrom> ;Journal of Oncology Pharmacy Practice. 2021 Apr 1
18 citations
Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma
Justin C. Moser, Guo Wei, Sarah Colonna, Kenneth F. Grossmann, Shiven B. Patel, John R. Hyngstrom> ;Acta Oncologica. 2020 Jan 10
41 citations
Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
Justin C. Moser, Danli Chen, Siwen Hu-Lieskovan, Kenneth F. Grossmann, Shiven B. Patel, Sarah Colonna, Jian Ying, John R. Hyngstrom> ;Cancer Medicine. 2019 Nov 2
4 citations
Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status.
Amanda Truong, John R. Hyngstrom, Robert H.I. Andtbacka, R. Dirk Noyes, Melissa Wright, John Snyder, Alyssa Winters, William T. Sause, Kenneth F. Grossmann, Hung T. Kh...> ;Melanoma Research. 2020 Apr 1
11 citations
Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.
Noelia Nebot, Hendrik-Tobias Arkenau, Jeffrey R. Infante, Jason C. Chandler, Andrew Weickhardt, Jason D. Lickliter, John Sarantopoulos, Michael S. Gordon, Gabriel Mak,...> ;British Journal of Clinical Pharmacology. 2018 Apr 1
10 citations
Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011)
Douglas Grossman, James M. Farnham, John R. Hyngstrom, Marki E. Klapperich, Aaron M. Secrest, Sarah Empey, Glen M. Bowen, David A. Wada, Robert H.I. Andtbacka, Kenneth...> ;Journal of the American Academy of Dermatology. 2018 Aug 1
20 citations
Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.
Laura J. Gardner, Morgan Ward, Robert H.I. Andtbacka, Kenneth M. Boucher, Glen M. Bowen, Tawnya L. Bowles, Adam L. Cohen, Kenneth F. Grossmann, Ying J. Hitchcock, Sher...> ;Melanoma Research. 2017 Oct 1
303 citations
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis o...
, , , , , , , , , , , , , , , > ;Journal of Clinical Oncology. 2017 Aug 25
353 citations
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-L...
James Larkin, David R. Minor, Sandra P. D'Angelo, Bart Neyns, Michael Smylie, Wilson H. Miller, Ralf Gutzmer, Gerald P. Linette, Bartosz Chmielowski, Christopher D. La...> ;Journal of Clinical Oncology. 2017 Jul 3
79 citations
Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.
Mariah M. Johnson, Sancy A. Leachman, Lisa G. Aspinwall, Lee D. Cranmer, Clara Curiel-Lewandrowski, Vernon K. Sondak, Clara E. Stemwedel, Susan M. Swetter, John T. Vet...> ;Melanoma Management. 2017 Mar 1
28 citations
Treatment‐related determinants of survival in early‐stage (T1–2N0M0) oral cavity cancer: A population‐based study
Justin C. Sowder, Richard B. Cannon, Luke O. Buchmann, Jason P. Hunt, Ying J. Hitchcock, Shane Lloyd, Kenneth F. Grossmann, Marcus M. Monroe> ;Head & Neck. 2017 May 1
28 citations
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Antonio Jimeno, Marshall R. Posner, Lori J. Wirth, Nabil F. Saba, Roger B. Cohen, Elizabeta C. Popa, Athanassios Argiris, Kenneth F. Grossmann, Ammar Sukari, Dawn Wils...> ;Cancer. 2016 Dec 1
666 citations
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled...
, , , , , , , , , , , , , , , , , , , > ;The Lancet. Oncology. 2016 Nov 1
52 citations
A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma
Abhijit Ray, Matthew A. Williams, Stephanie Meek, Randy C. Bowen, Kenneth F. Grossmann, Robert H.I. Andtbacka, Tawnya L. Bowles, John R. Hyngstrom, Sancy A. Leachman, ...> ;Oncotarget. 2016 Jul 6
13 citations
Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.
Straubhar, A. M., David D. Stenehjem, Michael Toole, Joseph Merriman, Kinjal Parikh, Stephanie Daignault, Sarah Scarlett, Peg Esper, Katherine A. Skinner, Aaron M. Uda...> ;Cancer Immunology, Immunotherapy. 2016 Jun 8
101 citations
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).
Christopher J. Anker, Kenneth F. Grossmann, Michael B. Atkins, Gita Suneja, Ahmad A. Tarhini, John M. Kirkwood> ;International Journal of Radiation Oncology, Biology, Physics. 2016 Jun 1
Join now to see all

Journal Articles

Prognostic Gene Expression Profiling in Cutaneous Melanoma
Douglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Joanne..., JAMA Dermatology

Authored Content

Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020

Press Mentions

Adjuvant Pembrolizumab Improves RFS, Not OS, in Resected High-Risk MelanomaJune 8th, 2021
SWOG Researchers to Present Practice-Changing Research at Virtual ASCO 2021June 1st, 2021